The clinical landscape concerning advanced prostate cancer is rapidly changing and reaching beyond androgen deprivation therapy and androgen receptor-targeted therapies. Taxane chemotherapy is a critical tool in the management of advanced prostate cancer. Additionally, novel drug classes, such as PARP inhibitors, are being investigated. In spite of the tremendous progress, resistance to therapy remains as a major impediment to further improvement. Resistance mechanisms appear diverse and are not fully known or understood. This review will highlight recent advances in research regarding mechanisms of resistance to both taxanes (such as increased drug efflux capacity) and PARP inhibitors (such as reversion mutations, which restore DNA-repair proficiency). Understanding resistance to therapy promises to remove barriers blocking progress toward improved patient outcomes.
|Original language||English (US)|
|Number of pages||7|
|Journal||Current Opinion in Endocrine and Metabolic Research|
|State||Published - Feb 2020|
- PARP inhibitor
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism